Apoptotic pathways in prostate cancer
References (151)
- et al.
Spermine prevents endonuclease activation and apoptosis in thymocytes
Exp. Cell Res.
(1991) - et al.
Identification of glutathione S-transferase Yb1 mRNA as the androgen repressed mRNA by cDNA cloning and sequence analysis
J. Biol. Chem.
(1987) - et al.
FADD, a novel death domain-containing protein, interacts with the death domain of Fas and initiates apoptosis
Cell
(1995) - et al.
Biochemical characterization of prostatic nuclei I. androgen-induced changes in nuclear proteins
Biochimica. Biophysica. Acta
(1971) - et al.
Polymerization of deoxyribonucleotides in relation to androgen-induced prostatic growth
Arch. Biochem. Biophys.
(1968) - et al.
Evidence for early induction of calmodulin gene expression in lymphocytes undergoing glucocorticoid-mediated apoptosis
J. Biol. Chem.
(1991) Survival factors, intracellular signal transduction, and the activation of endonucleases in apoptosis
Sem. Canc. Biol.
(1995)- et al.
Locally recurrent prostate tumors following either radiation therapy or radical prostatectomy have changes in Ki-67 labeling index, p53 and bcl-2 immunoreactivity
J. Urol.
(1998) - et al.
Differential requirement for caspase 9 in apoptotic pathways in vivo
Cell
(1998) Role of androgens in prostatic cancer
Thymine-less death in androgen independent prostatic cancer cells
Biochem. Biophys. Res. Commun.
(1989)
Regulation of nuclear scaffold protease activity by calcium
Exp. Cell Res.
(1990)
Combined analysis with bcl-2 and p53 immunostaining predicts poorer prognosis in prostatic carcinoma
J. Urol
(1997)
Bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation
Cell
(1989)
Bcl-2 Oncoprotein Blocks Chemotherapy- Induced Apoptosis in a Human Leukemia Cell Line
Blood
(1993)
Cleavage of retinoblastoma protein during apoptosis: interleukin-1β-converting enzyme-like protease as candidate
Cancer Res.
(1996)
Bcl-2 overexpression combined with p53 protein accumulation correlates with hormone-refractory prostate cancer
Brit. J. Cancer
(1996)
Death Receptors: Signaling and modulation
Science
(1998)
Cell proliferation, DNA repair, and p53 function are not required for programmed death of prostatic glandular cells induced by androgen ablation
Implication of the cell kinetic changes during the progression of human prostatic cancer
Clin. Cancer Res.
(1995)
Cell Death in Biology and Pathology
(1981)
Radiation-induced apoptosis mediated by retinoblastoma protein
Cancer Res.
(1998)
Cascade induction of c-fos, c-myc and heat shock 70K transcripts during regression of the rat ventral prostate gland
Mol. Endocrinol.
(1988)
Induction of the TRPM-2 gene in cells undergoing programmed death
Mol. Cell Biol.
(1989)
The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma
Brit. J. Urol.
(1997)
Role of p53 in apoptosis
Membrane topology of the Bcl-2 proto-oncogenic protein demonstrated in vitro
J. Biol. Chem.
(1990)
Apoptosis is associated with cleavage of a 5 kDa fragment from RB which mimics dephosphorylation and modulates E2F binding
Oncogene
(1997)
Thapsigargin analogues for targeting programmed death of androgen-independent prostatic cancer cells
Bioorg. Medicinal Chemistry
(1999)
Enzymatic activity of the prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors
Eur. J. Biochem.
(1990)
Caspases: the executioners of apoptosis
Biochem. J.
(1997)
Detection of the Apoptosis-Suppressing Oncoprotein bcl-2 in Hormone-Refractory Human Prostate Cancers
Am. J. Pathol.
(1993)
Calcium channel antagonists delay regression of androgen-independent tissues and suppress gene activity associated with cell death
Prostate
(1988)
Specific and efficient peptide substrates for assaying the proteolytic activity of prostate-specific antigen
Cancer Res.
(1997)
Enzymatic-Activation of prodrugs by prostate-specific antigen: targeted therapy for metastatic prostate cancer
The Cancer Journal from Scientific American
(1998)
Enzymatic-activation of a doxorubicin-peptide prodrug by prostate-specific antigen
Cancer Res.
(1998)
Inhibition of caspase activity does not prevent the signaling phase of apoptosis in prostate cancer cells
Prostate
(1999)
IAPs block apoptotic events induced by caspase-8 and cytochrome c by direct inhbition of distinct caspases
EMBO J.
(1998)
Intracellular free calcium related to apoptotic death in quail granulosa sheets kept in serum-free culture
Cell Death Different.
(1997)
Bilateral orchiectomy with or without flutamide for metastatic prostate cancer
New England J. Med.
(1998)
Relationship between DNA fragmentation and apoptosis in the programmed cell death in the rat prostate following castration
Prostate
(1989)
A Matter of life and cell death
Science
(1998)
Cell proliferation studies in the rat prostate: II. The effects of castration and androgen replacement upon basal and secretory cell proliferation
Prostate
(1987)
Induction and activation of tissue transglutaminase during programmed cell death
FEBS Lett.
(1989)
Fas and Fas ligand in embryos and adult mice: Ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover
J. Cell Biol.
(1996)
Differential gene regulation during programmed death (apoptosis) versus proliferation of prostatic glandular cells induced by androgen manipulation
Endocrinology
(1993)
The role of calcium, pH, and cell proliferation in the programmed (apoptotic) death of androgen-independent prostatic cancer cells induced by thapsigargin
Cancer Res.
(1994)
Proliferation-dependent vs. independent programmed cell death of prostatic cancer involves distinct gene regulation
The Prostate
(1994)
Androgen ablation induced programmed death of prostatic glandular cells does not involve recruitment into a defective cell cycle or p53 induction
Endocrinol.
(1995)
Expression of bcl-2 and the progression of human and rodent prostatic cancers
Clinical Cancer Res.
(1996)
Cited by (6)
What is the pathophysiology of a hormone-resistant prostate tumour?
2011, European Journal of CancerGnRH-antagonisten - Eine neue therapieoption beim fortgeschrittenen prostatakarzinom
2009, Aktuelle UrologieManagement of advanced prostate cancer: Can we improve on androgen deprivation therapy?
2008, BJU InternationalMolecular therapy intervention prospects in prostate cancer
2004, Current Pharmaceutical DesignRegulation of apoptosis in prostate cancer
2001, Cancer and Metastasis Reviews
Copyright © 2001 Published by Elsevier B.V.